A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.

Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

The second CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" for blood ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...

Opens in a new tab or window Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor (CAR) T-cell therapies for the potential ...

LONDON - Autolus Therapeutics plc (NASDAQ:AUTL), a biopharmaceutical company specializing in T cell therapies for cancer, has announced its participation in the upcoming 2025 Tandem Meetings | ...

A "living drug" Qartemi has been approved for blood cancer patients in India who suffer from an advanced or relapsed stage of ...